Table 3 Univariate analyses of prognostic factors for survival
Variables | No. of patients | Cumulative 12-month preogresion free survival rate | P | Cumulative 2-year overall survival rate | P |
|---|---|---|---|---|---|
Age | |||||
   < 50 | 22 | 49.0% | 0.725 | 50.0% | 0.152 |
   ≧50 | 35 | 68.6% | 68.0% | ||
Gender | |||||
   male | 55 | 61.5% | 0.878 | 65.2% | 0.553 |
   female | 2 | 50.0% | 50.0% | ||
Site | |||||
   oral cavity | 24 | 41.7% | 45.5% | 0.093 | |
   oropharynx | 21 | 66.7% | 0.101 | 66.6% | |
   Hypopharynx/larynx | 12 | 81.8% | 0.035* | 83.3% | |
Stage | |||||
   IVa | 10 | 80.0% | 0.119 | 90.0% | 0.049* |
   IVb | 47 | 57.2% | 54.7% | ||
T stage | |||||
   0-2 | 6 | 66.7% | 0.396 | 66.7% | 0.694 |
   3-4 | 51 | 60.5% | 60.3% | ||
N stage | |||||
   negative | 12 | 50.0% | 0.837 | 72.9% | 0.350 |
   positive | 45 | 57.3% | 57.8% | ||
Radiation | |||||
   ≦6000 cGy | 20 | 55.0% | 0.304 | 55.0% | 0.412 |
   > 6000 cGy | 37 | 64.5% | 64.1% | ||
Alcohol | |||||
   never | 11 | 63.6% | 1.000 | 63.6% | 0.754 |
   yes | 46 | 60.6% | 64.8% | ||
Smoking | |||||
   never | 9 | 66.7% | 0.614 | 66.7% | 0.679 |
   yes | 48 | 60.1% | 60.0% | ||
Betel nuts | |||||
   never | 20 | 70.0% | 0.638 | 74.0% | 0.123 |
   yes | 37 | 56.3% | 54.1% | ||
ERCC1 | |||||
   low expression | 31 | 73.7% | < 0.001* | 74.2% | 0.023* |
   high expression | 26 | 42.3% | 44.4% |